Scheller, Marina http://orcid.org/0000-0001-6108-0831
Ludwig, Anne Kathrin
Göllner, Stefanie
Rohde, Christian
Krämer, Stephen
Stäble, Sina http://orcid.org/0000-0002-5962-2440
Janssen, Maike
Müller, James-Arne
He, Lixiazi http://orcid.org/0000-0002-5279-7352
Bäumer, Nicole
Arnold, Christian
Gerß, Joachim
Schönung, Maximilian http://orcid.org/0000-0002-9778-9698
Thiede, Christian http://orcid.org/0000-0003-1241-2048
Niederwieser, Christian http://orcid.org/0000-0002-0114-1011
Niederwieser, Dietger http://orcid.org/0000-0002-4737-1103
Serve, Hubert
Berdel, Wolfgang E.
Thiem, Ulrich http://orcid.org/0000-0002-2181-6872
Hemmerling, Inga
Leuschner, Florian
Plass, Christoph
Schlesner, Matthias http://orcid.org/0000-0002-5896-4086
Zaugg, Judith http://orcid.org/0000-0001-8324-4040
Milsom, Michael D. http://orcid.org/0000-0002-3567-254X
Trumpp, Andreas http://orcid.org/0000-0002-6212-3466
Pabst, Caroline http://orcid.org/0000-0001-9716-5909
Lipka, Daniel B. http://orcid.org/0000-0001-5081-7869
Müller-Tidow, Carsten http://orcid.org/0000-0002-7166-5232
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (LI 2492/3-1, MU 1328/18‐1)
Deutsche Krebshilfe (70112974, 70113908)
Deutsche Jose Carreras Leukämie Stiftung
Article History
Received: 20 November 2020
Accepted: 19 April 2021
First Online: 25 May 2021
Competing interests
: The original AML-AZA clinical trial was partially supported by Celgene and Amgen (principal investigator, C.M.T.). The Department of Medicine V is further supported by multiple biopharmaceutical companies for clinical trials and translational research projects. C.T. is co-owner and CEO of AgenDix GmbH, a company performing molecular diagnostics. C.T. has served as an adviser and provided educational support for Celgene, JAZZ, Novartis and Astellas. All other authors declare no competing interests.